Luteolin exhibits anti-breast cancer property through up-regulating miR-203

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17:43–46.
   PubMedGoogle Scholar
• Shamsi M, Pirayesh Islamian J. Breast cancer: early diagnosis and effective treatment by drug delivery tracing. Nucl Med Rev. 2017;20:45–48.
   PubMed Web of Science ®Google Scholar
• Board PDQATE. Breast cancer treatment (PDQ(R)): patient version. PDQ cancer information summaries. Bethesda (MD): National Cancer Institute; 2002.
   Google Scholar
• Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018;225:342–358.
   PubMed Web of Science ®Google Scholar
• Nabavi SF, Braidy N, Gortzi O, et al. Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull. 2015;119:1–11.
   PubMed Web of Science ®Google Scholar
• Zang MD, Hu L, Fan ZY, et al. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway. J Transl Med. 2017;15:52.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lang T, Jin B, et al. Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study. J Proteomics. 2017;161:1–10.
   PubMed Web of Science ®Google Scholar
• Yao X, Jiang W, Yu D, et al. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway. Food Funct. 2019;10:703–712.
   PubMed Web of Science ®Google Scholar
• Wang H, Luo Y, Qiao T, et al. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. J Ovarian Res. 2018;11:93.
   PubMed Web of Science ®Google Scholar
• Cook MT. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer (Dove Med Press). 2018;10:89–100.
   PubMed Web of Science ®Google Scholar
• Bahiraee A, Ebrahimi R, Halabian R. The role of inflammation and its related microRNAs in breast cancer: a narrative review. J Cell Physiol. 2019. [Epub ahead of print]. doi: 10.1002/jcp.28742
   Google Scholar
• Uhr K, Prager-van der Smissen WJC, Heine AAJ, et al. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One. 2019;14:e0216400.
   PubMed Web of Science ®Google Scholar
• O’Bryan S, Dong S, Mathis JM, et al. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. Eur J Cancer. 2017;72:1–11.
   PubMed Web of Science ®Google Scholar
• Cui Y, Wang J, Liu S, et al. MiR-216a promotes breast cancer cell apoptosis by targeting PKCalpha. Fundam Clin Pharmacol. 2019;33:397–404.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu H, Wang J, et al. miR-4513 promotes breast cancer progression through targeting TRIM3. Am J Trans Res. 2019;11:2431–2438.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Hur K, et al. Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. J Cachexia Sarcopeni. 2019;10:536–548.
   PubMed Web of Science ®Google Scholar
• Simile MM, Peitta G, Tomasi ML, et al. MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes. Oncotarget. 2019;10:2835–2854.
   PubMedGoogle Scholar
• Li J, Zhang B, Cui J, et al. miR-203 inhibits the invasion and EMT of gastric cancer cells by directly targeting Annexin A4. Oncol Res. 2019;27:789–799.
   PubMed Web of Science ®Google Scholar
• Chen LZ, Ding Z, Zhang Y, et al. MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance. Eur Rev Med Pharmacol Sci. 2018;22:3734–3741.
   PubMed Web of Science ®Google Scholar
• Muhammad N, Bhattacharya S, Steele R, et al. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 2016;7:58595–58605.
   PubMedGoogle Scholar
• Wang C, Zheng X, Shen C, et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.
   PubMed Web of Science ®Google Scholar
• Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett. 2019;17:3842–3850.
   PubMed Web of Science ®Google Scholar
• Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39:935–946.
   PubMed Web of Science ®Google Scholar
• Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 2017;44:72–82.
   PubMed Web of Science ®Google Scholar
• Kabat GC, Ginsberg M, Sparano JA, et al. Risk of recurrence and mortality in a multi-ethnic breast cancer population. J Racial Ethn Health Disparities. 2017;4:1181–1188.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wang Y, Kiani MF, et al. Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer. 2016;16:335–343.
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Meng X, et al. Dietary natural products for prevention and treatment of breast cancer. Nutrients. 2017;9:728.
   PubMed Web of Science ®Google Scholar
• Shareef M, Ashraf MA, Sarfraz M. Natural cures for breast cancer treatment. Saudi Pharm J. 2016;24:233–240.
   PubMed Web of Science ®Google Scholar
• Park SH, Ham S, Kwon TH, et al. Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol. 2014;33:219–231.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.
   PubMed Web of Science ®Google Scholar
• Lin D, Kuang G, Wan J, et al. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep. 2017;37:895–902.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu P, Yu H, et al. Luteolin protects PC-12 cells from H2O2-induced injury by up-regulation of microRNA-21. Biomed Pharmacother. 2019;112:108698.
   PubMed Web of Science ®Google Scholar
• Jiang ZQ, Li MH, Qin YM, et al. Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microRNA-34a-5p. Int J Mol Sci. 2018;19:pii: E447.
   Web of Science ®Google Scholar
• Han K, Meng W, Zhang JJ, et al. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. OncoTargets Ther. 2016;9:3085–3094.
   PubMed Web of Science ®Google Scholar
• Sakurai MA, Ozaki Y, Okuzaki D, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One. 2014;9:e100124.
   PubMed Web of Science ®Google Scholar
• He S, Zhang G, Dong H, et al. miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. OncoTargets Ther. 2016;9:6203–6210.
   PubMed Web of Science ®Google Scholar
• Lin J, Wang L, Gao J, et al. MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor α-positive breast cancer cells. Exp Ther Med. 2017;14:2702–2708.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang B, Li W, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2:782–791.
   PubMedGoogle Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–1284.
   PubMed Web of Science ®Google Scholar